By Noemie Bisserbe

PARIS--French drugmaker Sanofi SA (SAN.FR) said Thursday it had received approval from the U.S. Food and Drug Administration for Adlyxin, a medicine indicated to treat adults with type 2 diabetes.

Adlyxin has already been approved under the proprietary name, Lyxumia in more than 60 countries and marketed in over 40, including most EU countries, Japan, Brazil, Mexico and India.

-Write to Noemie Bisserbe at noemie.bisserbe@wsj.com

(END) Dow Jones Newswires

July 28, 2016 01:27 ET (05:27 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Sanofi Charts.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Sanofi Charts.